Sponsor:
Regeneron Pharmaceuticals
Code:
NCT03936335
Conditions
Adverse Pregnancy Outcomes
Atopic Dermatitis
Eligibility Criteria
Sex: Female
Age: 18 - 49
Healthy Volunteers: Not accepted
Interventions
dupilumab
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-17. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2025-08-03.